Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Volume 9, Issue 12, Pages 4353-4370Publisher
ELSEVIER
DOI: 10.1016/j.jaip.2021.07.056
Keywords
Asthma; Eosinophilic; Health care resource use; ISAR; Phenotypes; Primary care; Severity; United Kingdom
Categories
Funding
- AstraZeneca
- Boehringer Ingelheim
- GlaxoSmithKline
- Sanofi
- A. Menarini
- Alk-Albello
- Allergy Therapeutics
- Anallergo
- MedImmune
- Boeh-ringer Ingelheim
- Chiesi Farmaceutici
- Circassia
- Danone
- Faes
- Genentech
- Gui-dotti Malesci
- Hal Allergy
- Merck
- MSD
- Mundipharma
- Novartis
- Orion
- Sanofi Aventis
- Genzyme/Regeneron
- Stallergenes
- UCB Pharma
- Uriach Pharma
- Teva
- Thermo Fisher
- Valeas
- Genentech/Hoffman Roche
Ask authors/readers for more resources
The study found that the eosinophilic asthma phenotype predominates in primary care in the UK, and is associated with greater asthma severity and healthcare resource use. These patients may benefit from earlier and targeted asthma therapy.
BACKGROUND: We developed an eosinophil phenotype gradient algorithm and applied it to a large severe asthma cohort (International Severe Asthma Registry). OBJECTIVE: We sought to reapply this algorithm in a UK primary care asthma cohort, quantify the eosinophilic phenotype, and assess the relationship between the likelihood of an eosinophilic phenotype and asthma severity/health care resource use (HCRU). METHODS: Patients age 13 years and older with active asthma and blood eosinophil count or 1 or greater, who were included from the Optimum Patient Care Research Database and the Clinical Practice Research Datalink, were categorized according to the likelihood of eosinophilic phenotype using the International Severe Asthma Registry gradient eosinophilic algorithm. Patient demographic, clinical and HCRU characteristics were described for each phenotype. RESULTS: Of 241,006 patients, 50.3%, 22.2%, and 21.9% most likely (grade 3), likely (grade 2), and least likely (grade 1), respectively, had an eosinophilic phenotype, and 5.6% had a noneosinophilic phenotype (grade 0). Compared with patients with noneosinophilic asthma, those most likely to have an eosinophilic phenotype tended to have more comorbidities (percentage with Charlson comorbidity index of >= 2: 28.2% vs 6.9%) and experienced more asthma attacks (percentage with one or more attack: 24.8% vs 15.3%). These patients were also more likely to have asthma that was difficult to treat (31.1% vs 18.3%), to receive more intensive treatment (percentage on Global Initiative for Asthma 2020 step 4 or 5: 44.2% vs 27.5%), and greater HCRU (eg, 10.8 vs 7.9 general practitioner all-cause consultations per year). CONCLUSIONS: The eosinophilic asthma phenotype predominates in primary care and is associated with greater asthma severity and HCRU. These patients may benefit from earlier and targeted asthma therapy. (C) 2021 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available